exon skipping

Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls

Long-term survival analysis comparing eteplirsen-treated Duchenne muscular dystrophy patients to matched natural history controls, demonstrating survival benefits with treatment.